Abstract
Active Surveillance (AS) is an accepted policy in several low-risk malignancies, such as prostate cancer, small renal tumours, and in clinical stage I seminomatous germ cell tumours.
Regarding Bladder Cancer (BC), Non-Muscle Invasive Bladder Cancer (NMIBC) accounts for ~50% of newly diagnosed cancers; although an high percentage of local recurrence has been reported in literature, only a small number of patients will progress to Muscle Invasive Bladder Cancer (MIBC). In this context, AS might be a reasonable strategy in patients presenting with small low-grade pTa/pT1a recurrent papillary BC, with acceptable risks of stage and grade progression. Recently the mid-term results from the BIAS (BIAS: Bladder cancer Italian Active Surveillance) Project, whose primary outcome was the check of adherence to AS its self have been published.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hardie C, Parker C, Norman A, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005;95:956–60.
Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU Int. 2015;115:216–22.
Yang G, Villalta JD, Meng MV, Whitson JM. Evolving practice patterns for the management of small renal masses in the USA. BJU Int. 2012;110:1156–61.
Lazzeri M, Guazzoni G. Early 21st Century renal cell carcinoma: a “paradigm shift”. Cancer. 2010;116:3080–3.
Heidenreich A. Clinical stage I nonseminomatous testicular germ-cell tumours: surgery or watchful waiting, still an issue? Curr Opin Urol. 2002;12:427–30.
Millan-Rodrıguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164:680–4.
Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170:438–41.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–7.
Rieken M, Xylinas E, Kluth L, et al. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol. 2014;65:201–9.
Martinez Caceres P, Hidalgo Arroyo JG, Chechile Toniolo GE. Is it necessary to always treat the relapses of superficial bladder tumour at the moment of diagnosis? Preliminary communication. Actas Urol Esp. 2005;29:567–71.
Gofrit ON, Shapiro A. Active surveillance of low grade bladder tumors. Arch Ital Urol Androl. 2008;80(4):132–5.
Pruthi RS, Baldwin N, Bhalani V, Wallen EM. Conservative management of low risk superficial bladder tumors. J Urol. 2008;179:87–90.
Hernandez V, Alvarez M, de la Peña E, et al. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology. 2009;73:1306–10.
De la Pena E, Hernandez V, Blazquez C, Perez E, Diaz FJ, Llorente C. Oncological safety of an active surveillance program in recurrent non muscle-invasive bladder tumour. J Urol. 2013;189(Suppl):e731.
Lozano F, Raventos C, Orsola A, et al. Active surveillance in low risk bladder cancer when TUR is recommended? J Urol. 2014;191(Suppl):e569.
Hernández V, Llorente C, de la Peña E, Pérez-Fernández E, Guijarro A, Sola I. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol. 2016;34(4):165.e19–23.
Hurle R, Pasini L, Lazzeri M, Colombo P, Buffi N, Lughezzani G, et al. Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project. BJU Int. 2016;118(6):935–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Hurle, R., Maccagnano, C., Forni, G. (2018). Active Surveillance for Low-Risk Non-Muscle Invasive Bladder Cancer. In: Soria, F., Gontero, P. (eds) Treating Urothelial Bladder Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-78559-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-78559-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78558-5
Online ISBN: 978-3-319-78559-2
eBook Packages: MedicineMedicine (R0)